Hypersensitivity reaction with multi-organ failure following re-exposure to rifampicin: case report and review of the literature including WHO spontaneous safety reports

被引:4
作者
Brockhaus, Lisa [1 ]
Schmid, Yasmin [2 ]
Rast, Anna C. [3 ]
Bravo, Alexandra E. Ratz [2 ,4 ]
Hofmeier, Kathrin Scherer [3 ]
Leuppi-Taegtmeyer, Anne B. [2 ,4 ]
机构
[1] Univ Hosp Basel, Dept Infect Dis, Basel, Switzerland
[2] Univ Hosp Basel, Dept Clin Pharmacol & Toxicol, Basel, Switzerland
[3] Univ Hosp Basel, Dept Dermatol, Allergy Unit, Basel, Switzerland
[4] Univ Hosp Basel, Dept Clin Pharmacol & Toxicol, Reg Pharmacovigilance Ctr, Basel, Switzerland
关键词
Rifampicin; Hypersensitivity reaction; Pneumonitis; Multi-organ failure; Pharmacovigilance; ACUTE-RENAL-FAILURE; DEPENDENT ANTIBODIES; HEMOLYTIC-ANEMIA;
D O I
10.1186/s40360-019-0289-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: True hypersensitivity reactions to rifampicin are relatively rare, nonetheless severe manifestations mostly involving a single organ have been documented. We report a case of acute multi-organ failure occurring after a medication error with re-exposure to rifampicin. Case presentation: A 68-year old patient developed acute hypersensitivity pneumonitis, acute renal failure, acute liver failure and haemolytic anemia within hours after a second re-exposure to Rifampicin for the treatment of a hip prosthesis infection with Staphylococcus epidermidis. A recent rifampicin exposure 1 week earlier had resulted in a massive rise of CRP levels without organ manifestations. Nine years previously, the patient had developed a multi-organ hypersensitivity reaction 8 days after commencing treatment with rifampicin for pulmonary tuberculosis; and 23 years previously he had received rifampicin without problems. The organ-specific hypersensitivity reactions were largely reversible after withdrawal of rifampicin and treatment with steroids. A review of the literature and summary of WHO spontaneous safety reports is also given. Conclusions: Re-exposure to rifampicin in sensitised individuals may cause acute severe hypersensitivity reactions. Due to its indications in the management of mycobacterial and implant-associated infections, rifampicin is a drug which might be given decades apart, which poses a risk that information about previous intolerance is lost.
引用
收藏
页数:6
相关论文
共 26 条
  • [1] Case Definition and Phenotype Standardization in Drug-Induced Liver Injury
    Aithal, G. P.
    Watkins, P. B.
    Andrade, R. J.
    Larrey, D.
    Molokhia, M.
    Takikawa, H.
    Hunt, C. M.
    Wilke, R. A.
    Avigan, M.
    Kaplowitz, N.
    Bjornsson, E.
    Daly, A. K.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (06) : 806 - 815
  • [2] [Anonymous], 2015, LAB PHARM S A
  • [3] [Anonymous], 2017, PIL PROGR SICH MED S, P1
  • [4] BODMER M, 2009, SCHWEIZ RUNDSCH MED, V98, P179, DOI DOI 10.1024/1661-8157.98.4.179
  • [5] Rifampicin-dependent antibodies bind a similar or identical epitope to glycoprotein IX-specific quinine-dependent antibodies
    Burgess, JK
    Lopez, JA
    Gaudry, LE
    Chong, BH
    [J]. BLOOD, 2000, 95 (06) : 1988 - 1992
  • [6] Rifampicin-induced acute renal failure: a series of 60 patients
    Covic, A
    Goldsmith, DJA
    Segall, L
    Stoicescu, C
    Lungu, S
    Volovat, C
    Covic, M
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (04) : 924 - 929
  • [7] Covic A, 2004, J INDIAN MED ASSOC, V102, P22
  • [8] Rifampicin-associated acute renal failure: Pathophysiologic, immunologic, and clinical features
    De Vriese, AS
    Robbrecht, DL
    Vanholder, RC
    Vogelaers, DP
    Lameire, NH
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (01) : 108 - 115
  • [9] Díaz-Pollán B, 2013, REV ESP QUIM, V26, P369
  • [10] GUPTA A, 1992, INT J LEPROSY, V60, P185